WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics (FORMA), a fully-integrated research and development biotechnology company, announced today an abstract featuring the company’s selective, small molecule IDH1m inhibitor, FT-2102, has been selected for an oral presentation at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from June 1-5, 2018 in Chicago, Illinois. Details on the presentation are included below.
Date and Time: Monday, June 4, 2018, 4:30 PM – 6:00 PM
Session Title: Targeted Therapy in Leukemia
Session Type: Oral Abstract Session
Title: A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Abstract No.: 7009
FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, neurodegeneration, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis, and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates providing profound patient benefit.
FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with operations in Watertown, MA and Branford, CT. www.formatherapeutics.com
Join our conversation on Twitter @FORMAInc.